Literature DB >> 11869432

CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia.

Takashi Kanbayashi1, Yuichi Inoue, Shigeru Chiba, Rika Aizawa, Yasushi Saito, Haruko Tsukamoto, Yukiharu Fujii, Seiji Nishino, Tetsuo Shimizu.   

Abstract

We measured cerebrospinal fluid (CSF) hypocretin-1 levels in 11 patients with narcolepsy-cataplexy, five with narcolepsy without cataplexy and 12 with idiopathic hypersomnia (IHS). All patients were Japanese. As reported in Caucasian patients, undetectable or very low hypocretin-1 levels were observed in most (9 out of 11) Japanese narcolepsy--cataplexy patients. Our hypocretin-deficient narcoleptics included three prepubertal cases within few months after the disease onset. All nine hypocretin-deficient patients were human leuckocyte antigen (HLA) DR2 positive, while two who had normal CSF hypocretin-1 levels were HLA DR2 negative. In contrast, none of the narcolepsy without cataplexy and IHS subjects had undetectable low levels. Low CSF hypocretin-1 is therefore very specific for HLA DR2 positive narcolepsy-cataplexy, and the deficiency is likely to be established at the early stage of the disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11869432     DOI: 10.1046/j.1365-2869.2002.00284.x

Source DB:  PubMed          Journal:  J Sleep Res        ISSN: 0962-1105            Impact factor:   3.981


  26 in total

1.  Low CSF hypocretin-1/orexin-A associated with hypersomnia secondary to hypothalamic lesion in a case of multiple sclerosis.

Authors:  Yasunori Oka; Takashi Kanbayashi; Takahiro Mezaki; Kazumi Iseki; Jun Matsubayashi; Gaku Murakami; Masaru Matsui; Tetsuo Shimizu; Hiroshi Shibasaki
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

2.  Dietary therapy restores glutamatergic input to orexin/hypocretin neurons after traumatic brain injury in mice.

Authors:  Jonathan E Elliott; Samuel E De Luche; Madeline J Churchill; Cindy Moore; Akiva S Cohen; Charles K Meshul; Miranda M Lim
Journal:  Sleep       Date:  2018-03-01       Impact factor: 5.849

3.  Validation of the ICSD-2 criteria for CSF hypocretin-1 measurements in the diagnosis of narcolepsy in the Danish population.

Authors:  Stine Knudsen; Poul J Jennum; Jørgen Alving; Søren Paludan Sheikh; Steen Gammeltoft
Journal:  Sleep       Date:  2010-02       Impact factor: 5.849

4.  Hypersomnia, asterixis and cataplexy in association with orexin A-reduced hypothalamic tumor.

Authors:  Kazuya Nokura; Takashi Kanbayashi; Toshihiko Ozeki; Hiroshi Koga; Takaaki Zettsu; Hiroko Yamamoto; Norio Ozaki; Tetsuo Shimizu; Tsukasa Kawase
Journal:  J Neurol       Date:  2004-12       Impact factor: 4.849

5.  Narcolepsy as an initial manifestation of neuromyelitis optica with anti-aquaporin-4 antibody.

Authors:  Toru Baba; Ichiro Nakashima; Takashi Kanbayashi; Masatoshi Konno; Toshiyuki Takahashi; Kazuo Fujihara; Tatsuro Misu; Atsushi Takeda; Yusei Shiga; Hiromasa Ogawa; Yasuto Itoyama
Journal:  J Neurol       Date:  2009-03-05       Impact factor: 4.849

6.  Neurosarcoidosis presenting as spontaneously remitting hypersomnia.

Authors:  Yoshihiko Nakazato; Sayaka Kondo; Aya Ohkuma; Yasuo Ito; Naotoshi Tamura; Nobuo Araki
Journal:  J Neurol       Date:  2009-07-16       Impact factor: 4.849

7.  Reward-seeking behavior in human narcolepsy.

Authors:  Alexandra Dimitrova; Rolf Fronczek; Janneke Van der Ploeg; Thomas Scammell; Shiva Gautam; Alvaro Pascual-Leone; Gert Jan Lammers
Journal:  J Clin Sleep Med       Date:  2011-06-15       Impact factor: 4.062

8.  CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome.

Authors:  Takashi Kanbayashi; Tohru Kodama; Hideaki Kondo; Shinsuke Satoh; Yuichi Inoue; Shigeru Chiba; Tetsuo Shimizu; Seiji Nishino
Journal:  Sleep       Date:  2009-02       Impact factor: 5.849

Review 9.  Clinical and neurobiological aspects of narcolepsy.

Authors:  Seiji Nishino
Journal:  Sleep Med       Date:  2007-04-30       Impact factor: 3.492

Review 10.  Benefits and risks of pharmacotherapy for narcolepsy.

Authors:  Merrill M Mitler; Roza Hayduk
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.